Know the Latest About COVID-19 Monoclonal Antibodies
August 2021
Rising cases will renew focus on COVID-19 monoclonal antibodies (casirivimab/imdevimab, etc) for treating mild to moderate illness.
Patients. Expect your hospital to follow emergency use authorization (EUA) criteria for COVID-19 "mabs" in most cases.
This means usually dispensing them for COVID-19 OUTpatients age 12 or older...with mild to moderate symptoms for less than 10 days...and at high risk of severe COVID-19 (diabetes, etc).
Practical advice for a better career, with unlimited access to CE
Hospital Pharmacy Technician's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote